You are subscribed to FDA Press Releases for U.S. Food & Drug Administration (FDA).
This information has recently been updated and is now available.
06/27/2014 03:24 PM EDT
The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal, or within 20 minutes after starting a meal.